Hallandale Pharmacy company profile: what is public, what is not

As of June 2026, Hallandale Pharmacy's public site does not disclose specific ownership or leadership names, funding history or investor detail, the exact founding year, how many provider accounts or patient prescriptions the pharmacy processes, or the full list of states where it holds active 503A shipping licensure. Where a fact is not in Hallandale's public materials, it is undisclosed rather than estimated here.

This is common for privately held compounding pharmacies and is not, by itself, a red flag. But it does mean a clinic's due diligence on these points has to come from direct requests during the provider account process rather than the website. The absence of public corporate detail simply shifts where you get your answers — from the site to the sales and onboarding conversation.

Because the corporate facts are not all public, request them during provider account setup: ask which legal entity you are contracting with, confirm Florida 503A licensure and any relevant state shipping licenses for your patient geography, and ask about the pharmacy's quality assurance practices — Certificates of Analysis, batch testing, and compounding standards. Ask for references from clinics of similar scale and prescription volume, and read the provider agreement and its terms for pricing, exclusivity, and exit before signing.

On the parts you can verify yourself, confirm the pharmacy is reachable at hallandalerx.com, that the partner portal is at partner.hallandalerx.com, that the formulary includes your top SKUs, and that the eRx transmission channels — LifeFile ERX, Surescripts, fax, or EMR API — match your clinic's workflow. For a transparent comparison point, Fizy Health publishes its model openly: pass-through per-vial 503A pricing shown before checkout, a disclosed facilitation fee, and LegitScript-certified partners — the kind of visibility worth looking for when a vendor's corporate detail requires direct inquiry.